Alto Neuroscience, Inc. (ANRO) Shareholder Equity
- 2026-06-30: Additional Paid in CapitalUSD $474.74M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $17.00K; Retained Earnings (Accumulated Deficit)USD $-255.51M; Stockholders' Equity Attributable to ParentUSD $219.25M.
- 2026-03-31: Additional Paid in CapitalUSD $471.22M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $13.00K; Retained Earnings (Accumulated Deficit)USD $-227.87M; Stockholders' Equity Attributable to ParentUSD $243.37M.
- 2025-12-31: Additional Paid in CapitalUSD $352.75M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $22.00K; Retained Earnings (Accumulated Deficit)USD $-201.63M; Stockholders' Equity Attributable to ParentUSD $151.14M.
- 2025-09-30: Additional Paid in CapitalUSD $296.99M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $14.00K; Retained Earnings (Accumulated Deficit)USD $-185.45M; Stockholders' Equity Attributable to ParentUSD $111.56M.
Alto Neuroscience, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Common Stock, Value, Outstanding USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | APIC, Share-based Payment Arrangement, Recognition and Exercise USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $474.74M | $17.00K | $-255.51M | $219.25M | $3.00K | 3 month · $115.00K | 3 month · $3.55M | 6 month · $0.00 | (m) |
| 2026-03-31 | $471.22M | $13.00K | $-227.87M | $243.37M | $3.00K | (m) | 3 month · $2.82M | 3 month · $0.00 | 3 month · $-190.00K |
| 2025-12-31 | $352.75M | $22.00K | $-201.63M | $151.14M | $3.00K | (m) | 12 month · $8.11M | 12 month · $524.00K | (m) |
| 2025-09-30 | $296.99M | $14.00K | $-185.45M | $111.56M | $3.00K | (m) | 3 month · $2.19M | 9 month · $524.00K | (m) |
| 2025-06-30 | $294.65M | $31.00K | $-171.27M | $123.41M | $3.00K | (m) | 3 month · $2.00M | 6 month · $524.00K | (m) |
| 2025-03-31 | $292.64M | $14.00K | $-153.56M | $139.10M | $3.00K | (m) | 3 month · $1.97M | 3 month · $524.00K | (m) |
| 2024-12-31 | $289.95M | $-101.00K | $-138.40M | $151.46M | $3.00K | (m) | 12 month · $7.63M | 12 month · $0.00 | (m) |
| 2024-09-30 | $288.34M | $-95.00K | $-123.19M | $165.05M | $3.00K | (m) | 3 month · $2.00M | 9 month · $0.00 | (m) |
| 2024-06-30 | $286.27M | $-89.00K | $-106.41M | $179.78M | $3.00K | 3 month · $23.00K | 3 month · $1.89M | 6 month · $0.00 | (m) |
| 2024-03-31 | $283.57M | $-84.00K | $-90.38M | $193.10M | $3.00K | (m) | 3 month · $2.18M | 3 month · $0.00 | (m) |
| 2023-12-31 | $5.37M | $-79.00K | $-76.97M | $-71.67M | $0.00 | (m) | 12 month · $2.89M | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | $-61.10M | (m) | (m) | 3 month · $541.00K | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | $-52.60M | (m) | (m) | 3 month · $1.26M | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | $-45.23M | (m) | (m) | 3 month · $484.00K | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | $-38.41M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |